ESRRA and breast carcinoma: ERR-α was previously identified as an adverse marker for breast cancer progression, indicating poor prognoses for ERR-α-positive tumors [62], and increased cancer cell migration, proliferation, and tumor development [63]; thus, this demonstrates that the ERR-α agonist can affect tumorigenesis.